Published in final edited form as:
Tetrahedron Lett. 2007 July 9; 48(28): 4809–4811.

Carbocyclic Sinefungin

Xueqiang Yin, **Guoxia Zhao**, and **Stewart W. Schneller***
Department of Chemistry and Biochemistry, Auburn University Auburn, Alabama 36849-5312

Abstract

(3a*S*,4*S*,6*R*,6a*R*)-Tetrahydro-2,2-dimethyl-6-vinyl-3a*H*-cyclopenta[*d*][1,3]-dioxol-4-ol, itself available from ribose, provided a convenient entry point for an 18-step preparation of carbocyclic sinefungin. This procedure is adaptable to a number of carbocyclic sinefungin analogs with diversity of heterocyclic base and in the amino acid bearing side chain.

Keywords

stereospecific allylboration; pyrazine protected aminoacid; Horeau method

Sinefungin (**1**)[1] is an amino acid-containing nucleoside isolated from the cultures of *Streptomyces griseolus*[2a] and *Streptomyces incarnatus*.[2b] The C-6′ primary amino center renders sinefungin structurally similar to S-adenosylmethionine (**2**, AdoMet). This resemblance has served as the mechanistic focal point for rationalizing sinefungin's *in vivo* and *in vitro* biological activities, including antiviral,[3–5] antifungal,[2,6] amoebicidal,[7] and antiparasitical,[8] through inhibition of, primarily,[3] AdoMet-dependent methyltransfrases.[4] However, the clinical promise of **1** is restricted by its *in vivo* toxicity.[9]

In our antiviral drug discovery program sinefungin represents an important target for structural modification in order to improve its therapeutic index. Among the many compounds, which have been synthesized and evaluated in the sinefungin series,[10] carbocyclic sinefungin (**3**) has been proven to be elusive.[11] This communication discloses a practical synthesis of **3** that is adaptable to analog development.

A retrosynthetic analysis of carbocyclic sinefungin led us to a convergent approach involving a purine base and an appropriately crafted (stereochemically and functionally) cyclopentane. Thus, protection of the secondary alcohol of **4**[12] to **5** was followed by hydroboration to provide the primary alcohol **6**. Oxidation of **6** by a modified Swern procedure gave aldehyde **7**. Calling on the Brown allylboration[13] **7** produced **8** in consistent yields (de 90% by NMR).

The side-chain stereochemistry of **8** was clarified by a modified Horeau method[14] using 2-phenylbutryl chloride, pyridine and DMAP as reagents. The recovered optically active 2-phenylbutanoic acid was *levorotatory*. Thus,[14b] the homoallylic configuration of **8** is *S*. This result is consistent with the *si* face selectivity for the Brown allylboration conditions used.[13]

Mesylation of **8** followed by sodium azide nucleophilic substitution produced **9**. Transformation of **9** into the azide-alcohol **10** was accomplished by sodium periodate glycolization/cleavage with, subsequent, Luche reduction ($NaBH_4/CeCl_3{\cdot}7\ H_2O$).[15] (It is to

*Corresponding author. Tel.: 334-844-5737; fax: 334-844-5748; e-mail: schnest@auburn.edu.

be noted that use of $NaBH_4$ alone in the last step of the **9** to **10** conversion led to an intractable mixture of two products.[16])

Derivative **10** was readily converted into the iodide **11** using the reagent obtained from iodine-imidazole. The lithium salt of (3*R*)-3,6-dihydro-2,5-dimethoxy-3-*iso*propylpyrazine reacted with **11** in the presence of Cu(I)[17] to provide the requisite **12** as one diastereomer (by NMR). Oxidative deprotection of the PMB ether group of **12** yielded **13**.

Use of the Mitsunobu reaction[18] to construct the purine conjugate (that is, with **13** and 6-chloropurine) was successful but the subsequent ammonolysis at the purine C-6 center yielded mostly decomposed materials. Thus, a more traditional nucleophilic coupling process was undertaken by derivatizing **13** as its triflate that was, in turn, treated with the sodium salt of adenine to yield **14**. Hydrolytic (acidic) removal of the pyrazine and *iso*propylidene units followed by azide reduction and saponification (of the methyl ester made available by breakdown of the pyrazine ring) led to achievement of carbocyclic sinefungin (**3**).[19]

Acknowledgements

This research was supported by funds from the NIH (AI 56540). The preliminary investigations of Tetyana Shulyak and Minmin Yang of the Auburn group assisted in the design of the successful synthesis described here.

References

1. (a) Ghosh AK, Liu W. J Org Chem 1996;61:6175. [PubMed: 11667452] and references cited therein. (b) Mucha A, Cappanelli M, Szczepanik W, Kaczmarek P, Skaa J, Jezowska-Bojczuk M. J Inorg Biochem 2006;100:178. [PubMed: 16359731]
2. (a) Hamill RL, Hoehn MM. J Antibiot 1973;26:463. [PubMed: 4792069]Florent, J.; Lunel, J.; Mancy, D. US Patent. 4,189,349. 1980.
3. Nagarajan, R. US Patent. 4,158,056. 1979.
4. (a) Pugh CS, Borchardt RT. Biochemistry 1982;21:1535. [PubMed: 6282307] (b) Pugh CSG, Borchardt RT, Stone HO. J Biol Chem 1978;253:4075. [PubMed: 659406]
5. Vedel M, Lawrence F, Robert-Gero M, Lederer E. Biochem Biophys Res Commun 1978;85:371. [PubMed: 217377]
6. Hamill, RL.; Nagarajan, R. US Patent 4,087,603. p. 1976
7. Ferrante A, Ljungström L, Huldt G, Lederer E. Trans Roy Soc Trop Med Hyg 1984;78:837. [PubMed: 6099924]
8. Trager W, Tershacovec M, Chiang PK, Cantoni GL. Exp Parasitol 1980;50:83. [PubMed: 6993216]
9. Zwyegarth E, Schillinger D, Kaufmann W, Röttcher D. Trop Med Parasitol 1986;37:255. [PubMed: 2878488]
10. See for example, (a) Barton DHR, Gero SD, Lawrence F, Robert-Gero M, Quiclet-Sire B, Samadi M. J Med Chem 1992;35:63. [PubMed: 1732534] (b) Barton DHR, Gero SD, Negron G, Quiclet-Sire B, Samadi M, Vincent C. Nucloesides Nucleotides 1995;14:1619. (c) Blanchard P, Dodic N, Fourrey JL, Lawrence F, Mouna AM, Robert-Gero M. J Med Chem 1991;34:2798. [PubMed: 1895298] (d) Marasco CJ Jr, Kramer DL, Miller J, Porter CW, Bacchi CJ, Rattendi D, Kucera L, Iyer N, Bernacki R, Pera P, Sufrin JR. J Med Chem 2002;45:5112. [PubMed: 12408722] (e) Maria EJ, da Silva AD, Fourrey JL. Eur J Org Chem 2000:627–631. (f) Secrist JA III, Talekar RR. Nucleosides Nucleotides 1990;9:619. (g) Lyga JW, Secrist JA III. J Org Chem 1983;48:1982. (h) Peterli-Roth P, Maguire MP, Leon E, Rapoport H. J Org Chem 1994;59:4186.
11. Gage, JL.; Priour, AA.; Savela, GC.; Miller, MJ. Abstracts of Papers, 216th National Meeting of the American Chemical Society; Boston, MA. August 23–27, 1998; Washington, DC: American Chemical Society; 1998. ORGN 314 (b) Da Silva AD, Maria EJ, Blanchard P, Fourrey JL, Robert-Gero M. Nucleosides Nucleotides 1998;17:2175.Miller, MJ.; Jin, B.; Warshakoon, NC.; Gage, JL. Abstracts of Papers, 226th National Meeting of the American Chemical Society; New York, NY. September 7–11, 2003; Washington, DC; ORGN 589: American Chemical Society; (d) Jiang MXW, Jin B, Gage JL, Priour A, Savela G, Miller MJ. J Org Chem 2006;71:4164. [PubMed: 16709056]

12. Yang M, Ye W, Schneller SW. J Org Chem 2004;69:3993. [PubMed: 15153042]
13. (a) Brown HC, Jadhav PK. J Am Chem Soc 1983;105:2092. (b) Brown HC, Bhat KS. J Am Chem Soc 1986;108:5919.
14. (a) Horeau A, Kagan HB. Tetrahedron 1964;20:2431. [PubMed: 5879220] (b) Barnekow DE, Cardellina JH II. Tetrahedron Lett 1989;30:3629.
15. Luche JL. J Am Chem Soc 1978;100:2226.
16. Boyer JH, Ellzey SE Jr. J Org Chem 1958;23:127.
17. Baldwin JE, Adlington RM, Mitchell MB. Tetrahedron 1995;51:5193.
18. (a) Mitsunobu O. Synthesis 1981:1. (b) Hughes DL. Org Prep Proced Int 1996;28:127.
19. Selected data for **3**: white foam; ^{1}H NMR (D_2O, 250 MHz) δ 8.23 (s, 1H), 8.18 (s, 1H), 4.80 (d, *J*=2.8 Hz, 1H), 4.58 (m, 1H), 4.03 (m, 2H), 3.70 (m, 1H), 2.56 (m, 1H), 2.26-1.73 (m, 8H); ^{13}C NMR (D_2O, 100 MHz) δ 188.5, 158.1, 154.9, 151.8, 143.4, 121.4, 77.42, 77.38, 62.54, 62.47, 52.9, 42.4, 42.3, 34.9, 27.06, 27.00; HRMS calcd for $C_{16}H_{24}N_6O_5$ [M-H_2O+H^+] 362.1945. Found: 362.1941.



Figure.



Scheme.

Reagents and conditions: *a*, PMBCl, NaH, DMF, 95%; *b*, (i) 9-BBN, THF; (ii) MeOH, H_2O_2, NaOH, 98% for two steps; *c*, SO_3·py, DMSO, DIPEA, CH_2Cl_2, 94%; *d*, (i) (+)-B-methoxydi*iso*pinocampheylborane, CH_2=$CHCH_2MgBr$, Et_2O/THF; (ii) MeOH, H_2O_2, NaOH, 96% for two steps; *e*, (i) MsCl, Et_3N, DMAP, CH_2Cl_2; (ii) NaN_3, DMF, 85% for two steps; *f*, (i) $NaIO_4$, OsO_4, MeOH/H_2O; (ii) $NaBH_4$, $CeCl_3$·7 H_2O, MeOH, 77% for two steps; *g*, TPP, imidazole, I_2, toluene/MeCN, 90%; *h*, (3*R*)-3,6-dihydro-2,5-dimethoxy-3-*iso*propylpyrazine, BuLi, CuCN, THF, 87%; *i*, DDQ, CH_2Cl_2/H_2O, 88%; *j*, (i) Tf_2O, pyridine, CH_2Cl_2; (ii) adenine, NaH, DMF, 45% for two steps; *k*, (i) 0.5 N HCl MeOH; (ii) $Pd(OH)_2$/C, cyclohexene; (iii) LiOH, MeOH/H_2O, 55% for three seps.